21
Integrase Strand Inhibitors (INSTIs)
Dolutegravir
(DTG)
Tivicay
®
50 mg once daily
OR
50 mg bid
No dosage
adjustment
necessary
Child-Pugh Class A/B:
• No dosage adjustment
Child-Pugh Class C:
• NOT recommended
Raltegravir
(RAL)
Isentress
®
HD
• 400 mg bid
(using Isentress
formulation), or
• 1200 mg once
daily (use Isentress
HD formulation
only)
• Do NOT
substitute
Isentress tablets
for Isentress HD
dosage.
No dosage
adjustment
necessary
Mild-to-Moderate
Hepatic Insufficiency:
• No dosage adjustment
necessary
Severe Hepatic
Insufficiency:
• No recommendation
Fusion Inhibitor
Enfuvirtide
(T20)
Fuzeon
®
90 mg subcutaneous
bid
No dosage
adjustment
necessary
No dosage adjustment
necessary
CCR5 Antagonist
Maraviroc
(MVC)
Selzentry
®
e recommended
dose differs based
on concomitant
medications and
potential for drug-
drug interactions.
CrCl <30 mL/min
or on HD:
Without Potent
CYP3A Inhibitors
or Inducers:
• 300 mg bid;
reduce to
150 mg bid
if postural
hypotension
occurs.
With Potent
CYP3A Inducers
or Inhibitors:
• NOT
recommended
No dosage
recommendations.
Concentrations will likely
be increased in patients
with hepatic impairment.
Table 6. Dosing of Antiretroviral Agents (cont'd)
ARVs
Generic Name
(Abbreviation)
Trade Name
Usual Daily
Dose
a
Dosing in Renal
Insufficiency
b
Dosing in Hepatic
Impairment
